Infinity's horizons broaden with rich AbbVie co-development deal

Infinity Pharmaceuticals will expand its capacity for single-agent and combination therapy oncology studies for duvelisib (IPI-145), and improve its ability to pay future milestone and royalty fees under prior agreements, through an $805m partnership with AbbVie.